Form 4 for ORKA Oruka Therapeutics, Inc.

Accepted 2024-08-20 00:00:00 ET · period of report 2024-08-16 · accession 0001437749-24-027344 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2024-08-20	2024-08-16	ORKA	Janus Henderson Biotech Innovation Master Fund Ltd	10%	P - Purchase	$2.93	+5,818	2.12M	+0.3%	+$17.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-08-16	P	A	5,390	$2.93	2,116,785	I By Fund	—	—	(F1) The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
2	Common	Common Stock	2024-08-16	P	A	428	$2.98	2,117,213	I By Fund	—	—	(F1) The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.